A marker can describe the likely course of a cancer or help identify differences in treatment benefit. Those roles require different evidence, and the same marker can have both.
A prognostic marker is associated with an outcome in a defined setting; a predictive marker identifies differences in treatment effect. Evidence for prediction needs a treatment comparison and assessment of how the treatment effect varies with the marker. A response association among people receiving one treatment can reflect prognosis or other differences. Statistical significance in one subgroup and nonsignificance in another does not by itself establish an interaction.
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit.
Shares Subgroup analysis (forest plots), Evidence from measurement to patient benefit.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Subgroup analysis (forest plots), Surrogate endpoint validation: which stand-ins have earned trust.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/